2 Growth Stocks That Are Beating Amazon Without Breaking a Sweat

Consider investing in these two growth stocks if you’re looking for stocks outperforming the likes of Amazon (NYSE:AMZN) by a margin this year.

| More on:
Upwards momentum

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

When it comes to growth stocks in the U.S. stock market, few companies have the reputation of delivering stellar returns than Amazon.com (NASDAQ:AMZN). However, big tech companies are not always winners for growth-seeking investors.

As of this writing, Amazon stock trades for US$114.56 per share, down by 32.77% year to date. Its decline is even worse than the S&P 500 Index’s 24.12% year-to-date decline.

Considering the series of interest rate hikes and persistent inflation, investors might not favour growth stocks at all right now. However, some businesses are outperforming Amazon and the broader market, despite the macroeconomic challenges. Today, I will discuss a U.S. stock and a Canadian stock that have been outperforming Amazon, which you can consider adding to your portfolio instead.

An American pharma company

Corcept Therapeutics (NASDAQ:CORT) is a US$2.84 billion market capitalization pharmaceutical company that engages in the discovery, development, and commercialization of drugs to treat severe metabolic, psychiatric, and oncologic disorders. The company primarily makes just one drug called Korlym, a medicine used to treat a hormonal disease called Cushing syndrome.

The company’s current product and various programs in the pipeline focus on cortisol, a naturally occurring molecule in the body.

Complications related to the production of this hormone have been implicated in several health conditions, and the company focuses on developing medicines that can treat them. The biopharma specialist company has three programs in phase three clinical trials, and these products could result in substantial revenues in the coming years.

The growth potential for the company is immense due to its innovative approach and subject matter expertise. While it might not deliver the same rapid growth as Amazon, it has undoubtedly been beating the e-commerce giant this year. Up by 30.19% year to date, the company expects to make between US$400 million and US$430 million in profits this year. It can be a strong bet to consider.

A Canadian retail giant

The retail industry is not where you might typically find growth stocks, and Alimentation Couche-Tard (TSX:ATD) is definitely a stock you might consider to be one. However, this boring Canadian retail stock has been outperforming Amazon stock by a massive margin this year on the TSX. As of this writing, Alimentation Couche-Tard stock trades for $55.78 per share, up by 7.08% year to date.

It is not a rapid-growth stock but rather a long-term bet to consider. In the decade between October 5, 2012, and October 7, 2022, its share prices have increased by almost 1,300%. The $57.01 billion market capitalization company is a global leader in convenience retail and has enjoyed immense success over the years in Canada.

The company’s management are masters at mergers and acquisitions, having slowly consolidated the global convenience store industry to deliver stellar growth over the years.

While it has not made recent acquisitions, it can splash more money, owing to its US$15 billion purchasing power. As the company continues raking in profits boosted by its organic same-store sales growth, it can drastically increase its purchasing power for further potential acquisition deals.

Foolish takeaway

Amazon, undoubtedly, is one of the biggest companies in the world today. It would take a lot for any other company to become outright bigger than Amazon. Suppose you seek massive long-term returns. In that case, investing in a business that is already a mammoth in the industry might not give you the same returns as smaller companies with massive growth potential.

Corcept Therapeutics stock and Alimentation Couche-Tard stock can be good investments for this purpose.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Adam Othman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alimentation Couche-Tard Inc. The Motley Fool recommends Amazon and Corcept Therapeutics. The Motley Fool has a disclosure policy.

More on Dividend Stocks

growing plant shoots on stacked coins
Dividend Stocks

5 Dividend Stocks to Buy With Yields Upwards of 5%

These five companies all earn tonnes of cash flow, making them some of the best long-term dividend stocks you can…

Read more »

funds, money, nest egg
Dividend Stocks

TFSA Investors: 3 Stocks to Start Building an Influx of Passive Income

A TFSA is the ideal registered account for passive income, as it doesn't weigh down your tax bill, and any…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

3 of the Safest Dividend Stocks in Canada

Royal Bank of Canada stock is one of the safest TSX dividend stocks to buy. So is CT REIT and…

Read more »

Growing plant shoots on coins
Dividend Stocks

1 of the Top Canadian Growth Stocks to Buy in February 2023

Many top Canadian growth stocks represent strong underlying businesses, healthy financials, and organic growth opportunities.

Read more »

stock research, analyze data
Dividend Stocks

Wherever the Market Goes, I’m Buying These 3 TSX Stocks

Here are three TSX stocks that could outperform irrespective of the market direction.

Read more »

woman data analyze
Dividend Stocks

1 Oversold Dividend Stock (Yielding 6.5%) to Buy This Month

Here's why SmartCentres REIT (TSX:SRU.UN) is one top dividend stock that long-term investors should consider in this current market.

Read more »

IMAGE OF A NOTEBOOK WITH TFSA WRITTEN ON IT
Dividend Stocks

Better TFSA Buy: Enbridge Stock or Bank of Nova Scotia

Enbridge and Bank of Nova Scotia offer high yields for TFSA investors seeking passive income. Is one stock now undervalued?

Read more »

Golden crown on a red velvet background
Dividend Stocks

2 Top Stocks Just Became Canadian Dividend Aristocrats

These two top Canadian Dividend Aristocrats stocks are reliable companies with impressive long-term growth potential.

Read more »